Here is some other vaccine news of note for the week.

Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.

China's ApolloBio increased upfront payment, while also terminating its right to buy into Inovio.

Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.

VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.

Here's some other vaccine news of note for the week.

Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.

Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.

Immunovaccine showed that its cancer vaccine, when paired with Incyte's epacadostat, might work in ovarian cancer.